基因分型市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、技術、應用、最終用途、地區和競爭細分，2020-2030 年預測

2024 年全球基因分型市場價值為 162.5 億美元，預計到 2030 年將達到 268.7 億美元，預測期內複合年成長率為 8.74%。全球基因分型市場是生物技術和生命科學領域中一個充滿活力且快速成長的領域。基因分型是一種確定個體基因組成（包括其 DNA 序列的變化）的過程。這些資訊對於個人化醫療和疾病研究到農業和祖先測試等廣泛的應用都至關重要。

預計基因分型市場將經歷成長，這得益於政府資金的增加，特別是政府機構對基因組研究的資助，以及製藥和生物技術公司為加速研究所做的貢獻。一個值得關注的例子是美國國立衛生研究院（NIH）於2018年9月向「我們所有人研究計畫」撥款2,860萬美元，用於在全美建立三個致力於精準醫學研究的基因組中心。

全球癌症和遺傳疾病等慢性病的增多，將推動基於基因型的診斷測試的需求。例如，世界衛生組織 (WHO) 報告稱，2020 年全球診斷出 1,910 萬例新癌症病例。此外，人類乳突病毒 (HPV) 和乙型肝炎病毒 (HBV)/丙型肝炎病毒 (HCV) 等致癌病毒造成了全球約 20% 的癌症相關死亡。由於人口成長和老化，未來二十年癌症病例數預計將增加約 70%。因此，癌症發生率的上升預計將成為該市場的重要驅動力。

主要市場促進因素

基因分型技術的進步

主要市場挑戰

數據管理和解釋

主要市場趨勢

多組學方法的整合

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球基因分型市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按產品（儀器、試劑和試劑盒、軟體和服務）
  • 依技術分類（PCR、毛細管電泳、微陣列、定序、質譜、其他）
  • 按應用（藥物基因組學、診斷和個人化醫療、農業生物技術、動物遺傳學、其他）
  • 按最終用途（製藥和生物製藥公司、診斷和研究實驗室、學術機構、其他）
  • 按地區
  • 按公司分類（2024）
• 產品市場圖
  • 按產品
  • 依技術分類
  • 按應用
  • 按最終用途
  • 按地區

第 6 章：北美基因分型市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲基因分型市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 法國
  • 義大利
  • 西班牙

第 8 章：亞太地區基因分型市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 日本
  • 印度
  • 澳洲
  • 韓國

第 9 章：南美洲基因分型市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲基因分型市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 科威特

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 合併與收購
• 產品發布

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN NV
• F Hoffmann-La Roche AG
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific Inc.
• GE HealthCare
• Bio-Rad Laboratories Inc.
• Standard BioTools(TM)

第 15 章：策略建議

第16章調查會社について,免責事項

Global Genotyping Market was valued at USD 16.25 billion in 2024 and is expected to reach USD 26.87 billion by 2030 with a CAGR of 8.74% during the forecast period. The global genotyping market is a dynamic and rapidly growing sector within the field of biotechnology and life sciences. Genotyping is the process of determining an individual's genetic makeup, including variations in their DNA sequence. This information is crucial for a wide range of applications, from personalized medicine and disease research to agriculture and ancestry testing.

The genotyping market is expected to experience growth driven by increased government funding, particularly for genomic research from governmental bodies, as well as contributions from pharmaceutical and biotechnology companies, aimed at expediting research. A noteworthy example of this is the National Institutes of Health (NIH) granting USD 28.6 million in September 2018 to the "All of Us Research Program" for establishing three genome centers across the United States dedicated to precision medicine research.

The global rise in chronic diseases, including cancer and genetic disorders, is set to fuel the demand for genotypic-based diagnostic testing. To illustrate, the World Health Organization (WHO) reported 19.1 million new cancer cases diagnosed worldwide in 2020. Moreover, cancer-causing viruses like Human Papilloma Virus (HPV) and Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) are responsible for approximately 20% of cancer-related deaths on a global scale. The number of cancer cases is projected to increase by roughly 70% over the next two decades, driven by population growth and aging. Therefore, the increasing prevalence of cancer is expected to be a significant driving force for this market.

Key Market Drivers

Advancements in Genotyping Technologies

Genotyping, the process of analyzing an individual's genetic makeup, is undergoing a revolution thanks to advancements in genotyping technologies. These innovations have not only enhanced the efficiency and accuracy of genotyping but also expanded its applications across various sectors, including healthcare, research, agriculture, and personalized medicine. One of the most significant factors propelling the genotyping market forward is the advent of high-throughput genotyping platforms. These platforms can analyze thousands or even millions of genetic markers in a single experiment, significantly increasing the speed and cost-effectiveness of genotyping. Researchers and clinicians can process larger datasets quickly, making genotyping accessible for a wide range of applications.

Next-generation sequencing, or NGS, is a game-changer in genotyping. It allows for the simultaneous sequencing of a person's entire genome, making it possible to identify even the rarest genetic variations. NGS is not only faster and more affordable than traditional Sanger sequencing, but it also generates vast amounts of data, enabling comprehensive genomic analysis. This technology has become essential in research, clinical diagnostics, and personalized medicine. Advancements in genotyping technologies have significantly improved the accuracy and resolution of genotyping results. Single nucleotide polymorphism (SNP) genotyping, for example, has become highly accurate, making it an invaluable tool in identifying genetic markers associated with diseases, drug responses, and other traits. This precision has bolstered the credibility of genotyping in both research and clinical applications.

Key Market Challenges

Data Management and Interpretation

One of the primary challenges in the genotyping market is the management and interpretation of the massive amounts of genetic data generated. Genotyping technologies, especially high-throughput platforms and next-generation sequencing, produce enormous datasets. The efficient analysis and interpretation of this data requires robust bioinformatics tools and skilled personnel, making data management a significant hurdle.

Key Market Trends

Integration of Multi-Omics Approaches

Genotyping is increasingly being integrated with other omics technologies such as proteomics and metabolomics. This holistic approach allows researchers to gain a more comprehensive understanding of biological systems. By analyzing genetic, protein, and metabolic data together, researchers can uncover intricate relationships and potential biomarkers for various diseases and conditions.

Key Market Players

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN N.V.
• F Hoffmann-La Roche AG
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific Inc.
• GE HealthCare
• Bio-Rad Laboratories Inc.
• Standard BioTools(TM)

Report Scope:

In this report, the Global Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genotyping Market, By Product:

• Instruments
• Reagents & Kits
• Software and Services

Genotyping Market, By Technology:

• PCR
• Capillary Electrophoresis
• Microarrays
• Sequencing
• Mass Spectrometry
• Others

Genotyping Market, By Application:

• Pharmacogenomics
• Diagnostics and Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Others

Genotyping Market, By End Use:

• Pharmaceutical and Biopharmaceutical Companies
• Diagnostics and Research Laboratories
• Academic Institutes
• Others

Genotyping Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genotyping Market.

Available Customizations:

Global Genotyping market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genotyping Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 5.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 5.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 5.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Technology
  • 5.3.3. By Application
  • 5.3.4. By End Use
  • 5.3.5. By Region

6. North America Genotyping Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 6.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 6.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 6.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genotyping Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Genotyping Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Genotyping Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe Genotyping Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 7.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 7.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 7.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genotyping Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. United Kingdom Genotyping Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. France Genotyping Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Genotyping Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Genotyping Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia-Pacific Genotyping Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 8.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 8.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 8.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Genotyping Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. Japan Genotyping Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. India Genotyping Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. Australia Genotyping Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. South Korea Genotyping Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. South America Genotyping Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 9.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 9.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 9.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Genotyping Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Genotyping Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Genotyping Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Genotyping Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product (Instruments, Reagents & Kits, Software and Services)
  • 10.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 10.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 10.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Genotyping Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Genotyping Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Genotyping Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use
  • 10.3.4. Kuwait Genotyping Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Technology
      • 10.3.4.2.3. By Application
      • 10.3.4.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Illumina Inc.
• 14.3. QIAGEN N.V.
• 14.4. F Hoffmann-La Roche AG
• 14.5. Danaher Corporation
• 14.6. Agilent Technologies, Inc.
• 14.7. Eurofins Scientific Inc.
• 14.8. GE HealthCare
• 14.9. Bio-Rad Laboratories Inc.
• 14.10. Standard BioTools(TM)

15. Strategic Recommendations

16. About Us & Disclaimer